Compare ASML Holding NV (ASML) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASML Holding NV vs Sana Biotechnology Inc — how do they compare? ASML Holding NV trades at $1,811.25 (market cap $689.17B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: ASML Holding NV is far larger — about 609.9× Sana Biotechnology Inc's market cap, and ASML Holding NV pays a 0.5% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ASML | SANA | |
|---|---|---|
Market Cap | $689.17B | $1.13B |
Sector | Technology | Health |
52-Week High | $1.99K | $5.92 |
52-Week Low | $725.85 | $2.68 |
Enterprise Value | $682.70B | $1.05B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,810.93, up 4.47% today, with a bullish technical signal from moving averages and strong analyst consensus. The stock is near its pivot point of $1,799, with resistance at $1,820. Recent earnings beat expectations in Q1 and Q2 2026, and revenue grew to $32.67 billion in 2025. The company maintains high profitability with a net margin of 27.78% and robust cash flow from operations of $12.66 billion.
Outlook remains positive due to AI-driven semiconductor demand, but risks include high valuation multiples and geopolitical tensions affecting Chinese business. Analysts see upside to a $2,390 consensus target, with 57% recommending buy. Institutional interest is strong, though the stock faces overbought signals on short-term RSI.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
